Pay in 4 interest-free payments of $5.28 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Research shows benefits emerge within weeks, with most weight loss occurring in the first 3-6 months of consistent treatment
The treatment (Victoza or placebo) was unblinded after the 26-week visit, and the trial was continued for an additional 26-week open-label extension
FDA safety-risk list
Endogenous Glucagon-like peptide-1 suppresses high-fat food intake by reducing synaptic drive onto mesolimbic dopamine neurons
1/5 Since:2022-07-25 Address:Room 901, Building 11, Lane 388, Baifu Road, Fengxian District, Shanghai, Sigma Audley New Material Technology Co., Ltd
ABSTRACT: Glucagon-like peptide-1 (GLP-1) receptor agonists are an increasingly popular class of glucose-lowering agents for the treatment of type 2 diabetes (T2DM), owing to their robust glucose-lowering effects, low risk of hypoglycemia, and potential to induce weight loss
US$ 25.97
US$ 29.51
US$ 29.59
US$ 27.62
US$ 25.36
US$ 21.32
